Tokuda Hospital
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Physiological Processes
At Tokuda Hospital in Sofia, research in cardiology focuses on persistent symptomatic atrial fibrillation and hypertrophic cardiomyopathy, with studies aimed at improving symptom control, reducing arrhythmia recurrence, and testing whether earlier intervention or new treatment approaches can offer better outcomes.
- Early treatment strategies for persistent atrial fibrillation
- Comparing catheter ablation with antiarrhythmic medication
- Relief of symptoms and functional limitations in hypertrophic cardiomyopathy
These trials explore both treatment effectiveness and patient quality of life, reflecting a strong interest in practical advances for heart rhythm disorders and structural heart disease.
Digestive System Diseases, Immune System Diseases, and Virus Diseases
The site’s gastroenterology and broader internal medicine research includes moderately to severely active Crohn's disease, chronic hepatitis B virus infection, and non-alcoholic steatohepatitis, with trials designed to evaluate new therapies, measure disease improvement, and better understand long-term safety in chronic inflammatory and liver conditions.
- Testing treatment options for Crohn’s disease
- Assessing antiviral control in chronic hepatitis B
- Evaluating therapy for non-alcoholic steatohepatitis and liver fibrosis
This area highlights the clinic’s involvement in diseases that affect the digestive tract, immune regulation, and liver health, where the goal is often to improve disease control and prevent progression.
Neoplasms
Oncology research at Tokuda Hospital includes studies in diffuse large B-cell lymphoma, follicular lymphoma, ER+, HER2- metastatic breast cancer, and lung cancer, with a clear emphasis on testing new cancer treatments and comparing them with established standards of care.
- New treatment combinations for lymphoma
- Therapies for relapsed or untreated blood cancers
- Comparative studies in metastatic breast cancer and lung cancer
These trials are aimed at improving survival, response rates, and disease control in both solid tumors and hematologic malignancies.
Respiratory Tract Diseases and Nutritional and Metabolic Diseases
The research portfolio also covers acute respiratory distress syndrome and metabolic liver disease, especially non-alcoholic steatohepatitis, showing interest in both severe acute illness and chronic metabolic complications.
- Supportive treatment for severe respiratory failure linked to infection
- Therapies targeting inflammation and fibrosis in liver disease
- Evaluating safety alongside clinical benefit in difficult-to-treat conditions
These studies focus on whether new interventions can improve outcomes in high-risk patients with serious breathing problems or progressive metabolic disease.
Musculoskeletal Diseases and Immune System Diseases
Immunology-focused research includes atopic dermatitis and multiple sclerosis, with trials centered on controlling chronic immune-mediated disease, reducing flares or progression, and evaluating longer-term treatment safety and flexibility.
- Improving skin disease control in atopic dermatitis
- Long-term safety follow-up in multiple sclerosis
- Adjusting treatment to match patient response
This reflects a broader commitment to immune-related disorders where the main goals are sustained symptom relief, safer maintenance therapy, and better everyday function.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1F. Hoffmann-La Roche AG1active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tokuda Hospital
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age with Functional Constipation (FC). | AbbVie Deutschland GmbH & Co. KG | Phase II | Not Recruiting | Dec 2023 | May 2025 |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Linaclotide | 2 | Unknown | 2023-12-05 | 2024-02-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
